

## Talzenna® (talazoparib) – New drug approval

- On October 16, 2018, <u>Pfizer announced</u> the <u>FDA approval</u> of <u>Talzenna (talazoparib)</u> for the
  treatment of adult patients with deleterious or suspected deleterious germline breast cancer
  susceptibility gene (BRCA)-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)negative locally advanced or metastatic breast cancer.
  - Select patients for therapy based on an FDA-approved companion diagnostic for Talzenna.
- Talzenna is an inhibitor of certain poly (ADP-ribose) polymerase (PARP) enzymes, which play a role
  in DNA repair. *In vitro* studies have shown that Talzenna-induced cytotoxicity results in DNA
  damage, decreased cell proliferation, and apoptosis.
- The safety and efficacy of Talzenna are based on data from an open-label clinical study of 431
  patients with gBRCAm HER2- negative locally advanced or metastatic breast cancer. Patients
  received Talzenna or provider's choice of chemotherapy. The major efficacy outcome measure was
  progression-free survival (PFS).
  - A statistically significant improvement in PFS was demonstrated for Talzenna (8.6 months) vs. chemotherapy (5.6 months) (HR = 0.54, 95% CI: 0.41, 0.71; p < 0.0001).</li>
  - The overall survival data were not mature at the time of the final PFS analysis (38% of patients had died).
- Warnings and precautions of Talzenna include myelodysplastic syndrome/acute myeloid leukemia, myelosuppression, and embryo-fetal toxicity.
- The most common adverse reactions (≥ 20%) reported with Talzenna use were fatigue, anemia, nausea, neutropenia, headache, thrombocytopenia, vomiting, alopecia, diarrhea, decreased appetite.
- The most common laboratory abnormalities (≥ 25%) with Talzenna use were decreases in hemoglobin, platelets, neutrophils, lymphocytes, leukocytes, and calcium; and increases in glucose, alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase.
- The recommended dose of Talzenna is 1 mg taken as a single daily dose, with or without food.
  - Patients should be treated until disease progression or unacceptable toxicity occurs.
- Pfizer plans to launch Talzenna on October 29, 2018. Talzenna will be available as 0.25 mg and 1 mg capsules.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.